Improved analogs and novel delivery systems for somatostatin octapeptides

J. P. Moreau, S. Kim, J. Z. Dong, F. Ignatious, S. Jackson, S. C. Moreau, B. A. Morgan, F. Touraud, J. E. Taylor, B. Tissier, M. Pellet, W. Murphy, T. Davis

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

Appropriate N-terminus modification can result in somatostatin (SRIF) octapeptide analogs that are both more potent and more selective in vitro for the human SRIF receptor type 2 (hsst2). In addition, these modifications can improve the duration of action and bioavailability of SRIF analogs following parenteral administration, as shown by both pharmacological and distribution studies in vivo with BIM-23190 and BIM-23197 in the rat.

Original languageEnglish (US)
Pages (from-to)24-26
Number of pages3
JournalMetabolism: Clinical and Experimental
Volume45
Issue numberSUPPL.1
DOIs
StatePublished - Jan 1 1996
Externally publishedYes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Improved analogs and novel delivery systems for somatostatin octapeptides'. Together they form a unique fingerprint.

  • Cite this

    Moreau, J. P., Kim, S., Dong, J. Z., Ignatious, F., Jackson, S., Moreau, S. C., Morgan, B. A., Touraud, F., Taylor, J. E., Tissier, B., Pellet, M., Murphy, W., & Davis, T. (1996). Improved analogs and novel delivery systems for somatostatin octapeptides. Metabolism: Clinical and Experimental, 45(SUPPL.1), 24-26. https://doi.org/10.1016/S0026-0495(96)90074-8